Title: Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma.
Journal: Journal of cancer research and clinical oncology 20180401
Title: Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Journal: Expert opinion on investigational drugs 20180101
Title: The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.
Journal: The Journal of biological chemistry 20161014
Title: Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Journal: Oncotarget 20160906
Title: Mantle Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20160410
Title: Label-Free Bottom-Up Proteomic Workflow for Simultaneously Assessing the Target Specificity of Covalent Drug Candidates and Their Off-Target Reactivity to Selected Proteins.
Journal: Chemical research in toxicology 20160119
Title: Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Journal: Blood 20150924
Title: Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
Journal: Drugs 20150501
Title: Ibrutinib in pretreated Waldenström's macroglobulinaemia.
Journal: The Lancet. Oncology 20150501
Title: Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
Journal: Leukemia 20150401
Title: Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20150201
Title: Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.
Journal: Proceedings of the National Academy of Sciences of the United States of America 20140805
Title: Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).
Journal: Leukemia & lymphoma 20131101
Title: Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.
Journal: Leukemia & lymphoma 20130801
Title: Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
Journal: The New England journal of medicine 20130704
Title: Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.
Journal: Expert review of clinical immunology 20130601
Title: Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials.
Journal: Current hematologic malignancy reports 20130301
Title: Ibrutinib and novel BTK inhibitors in clinical development.
Journal: Journal of hematology & oncology 20130101
Title: Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.
Journal: Cancer journal (Sudbury, Mass.) 20120901
Title: Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
Journal: Blood 20120830
Title: Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.
Journal: Cancer cell 20120612
Title: The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
Journal: Blood 20120315
Title: Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.
Journal: Current hematologic malignancy reports 20120301
Title: Novel targeted therapies for mantle cell lymphoma.
Journal: Oncotarget 20120201
Title: Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma.
Journal: Neoplasia (New York, N.Y.) 20111101
Title: Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Journal: Blood 20110609
Title: Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor.
Journal: International immunopharmacology 20110401
Title: The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.
Journal: Arthritis research & therapy 20110101
Title: More than just B-cell inhibition.
Journal: Arthritis research & therapy 20110101
